Dr James L Januzzi
Cardiologist, Massachusetts General Hospital. Prof of Medicine, Harvard Medical School
Related Links
- CANVAS (CANagliflozin cardioVascular Assessment Study): NT-proBNP and CVD risk reduction
- FAQ: NT-proBNP Interpretation in Multiple Scenarios
- FAQ: NT-proBNP vs Cardiac Medications
- FAQ: Role of NT-proBNP in Heart Failure Management
- How will NT-proBNP testing evolve in the future?
- Reference ranges for NT-proBNP & hs-TnT in Asian populations
- BNP vs NT-proBNP: An Expert View
- Natriuretic Peptide Measurement during ARNi Treatment
- Impact of ARNi Therapy on Natriuretic Peptide Use
- NT-proBNP in Hospital & Ambulatory Settings: Evidence to Clinical Practice
- Management of Cardiovascular Risks of COVID-19 Patients
- How NT-proBNP Made a Difference: Dr Januzzi’s Patient Story
- Natriuretic Peptides in the Latest ESC & AHA HF Guidelines
